Roche Diabetes Care committed to supporting people with diabetes in UK & Ireland
26 September 2019
- Vision for integrated diabetes management and joined up care aligns with population health goal
- Innovating across broad portfolio, including glucose monitoring, insulin pumps, digital solutions and lifestyle change programme
- Company investing in team expertise, and reviewing ways of working to meet future customer needs
Diabetes needs to be addressed with an integrated, collaborative and personalised approach in order to cover all the different angles of this complex condition and meet the individual goals of each person with diabetes or at risk of developing the disease. This is the vision of Roche Diabetes Care and we believe it aligns with the population health approach being taken by health systems around the world, with the NHS at the forefront.
The diabetes sector is crowded, this competition has fostered innovation but has also led to established players withdrawing in recent times. The only constant of our 40 years business activity in diabetes care is constant change, this is why we continue to adapt our ways of working. Today we have announced plans to consult with employees across our organisation on how we can structure our teams, and assess our skills, to be able to continue meeting customer needs in the best way possible.
Our portfolio is broad and developing, with new products and services coming on-board:
- Blood Glucose Monitoring – our systems are being enhanced by connectivity with the mySugr digital companion.
- Insulin Pumps – the recent launch of the Accu-Chek Solo micropump offers real choice for people with type 1 diabetes by offering more discretion and flexibility than ever before
- CGM – we distribute the world’s only long-lasting, implantable continuous glucose monitor, Eversense XL, and continue to establish further centres of excellence to expand availability
- Lifestyle Change – after a year of co-working, we have renewed our partnership with the dynamic start-up, OurPath, and will support the roll-out of the proven lifestyle change programme to support those living with, or at risk of type 2 diabetes
It is our ambition to deliver integrated diabetes management, harnessing our broad portfolio, and working with partners. At the same time, there is a shift in the decision making process in health systems towards those who think about health at a population level. In response to this, our management team, under the leadership of Managing Director Michael Goetzl, has implemented a new structure and new ways of working following consultation with employees over the summer.
Commenting, Michael Goetzl, said:
“In January, when I moved to our UK & Ireland organisation, I could not have arrived at a more exciting time as within days the NHS Long Term plan was published and so changes which had been in progress for some time began to accelerate. I can see that the Roche Diabetes Care vision for the integration of care, offering joined up solutions, is very much aligned with the goals of the NHS, HSE and health systems around the world.
I look forward to continued partnership and will ensure that in our team we have the expertise and are ready to continue working with those in the health system who drive change. Through this process, your local contact may have changed and if you are in any doubt about who to speak to, please do get in touch through our website.”
About Roche Diabetes Care
Roche Diabetes Care is pioneering innovative diabetes technologies and services since more than 40 years. Being a global leader in integrated diabetes management, more than 5,000 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target range and experience true relief from the daily therapy routines. Roche Diabetes Care collaborates with caregivers, healthcare providers and payers to optimally manage this complex condition and contribute to sustainable care structures. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, deliver insulin and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices, digital solutions, Roche Diabetes Care will enable optimal personalised diabetes management and thus improve therapy outcomes. Since 2017, mySugr with its world leading mobile diabetes management app and services is part of Roche Diabetes Care. For more information please visit www.accu-chek.co.uk.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
For more information please contact:
- Conn O’Neill, Public Affairs Lead (firstname.lastname@example.org / +44 (0)7525 765976
All trademarks used or mentioned in this release are protected by law.